Document is current
Any future updates will be listed below
-
Authors
Luna, Alejandro https://orcid.org/0000-0003-2201-3091
Devlin, Sean M. https://orcid.org/0000-0002-6801-720X
Rejeski, Kai https://orcid.org/0000-0003-3905-0251
Flynn, Jessica R.
Corona, Magdalena
Luttwak, Efrat https://orcid.org/0000-0003-0212-2135
Rivas-Delgado, Alfredo
Landego, Ivan
Cassanello, Giulio
Gomez-Llobell, Marina https://orcid.org/0009-0002-3116-0915
Raj, Sandeep S.
Dahi, Parastoo B. https://orcid.org/0000-0002-0794-3226
Lin, Richard J. https://orcid.org/0000-0002-0834-7880
Parascondola, Allison
Palomba, M.Lia https://orcid.org/0000-0001-5099-9156
Shah, Gunjan L. https://orcid.org/0000-0002-9977-0456
Scordo, Michael
Alarcon Tomas, Ana https://orcid.org/0000-0002-6290-1061
Leithner, Doris
Bedmutha, Akshay https://orcid.org/0000-0001-5683-4918
Schöder, Heiko
Imber, Brandon S. https://orcid.org/0000-0002-1281-5915
Salles, Gilles https://orcid.org/0000-0002-9541-8666
Park, Jae H. https://orcid.org/0000-0002-2903-5130
Perales, Miguel-Angel https://orcid.org/0000-0002-5910-4571
Shouval, Roni https://orcid.org/0000-0001-9827-8032
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K08CA282987, P30CA008748)
- License Information
-
More Information
Article History
Received: 24 December 2024
Revised: 20 March 2025
Accepted: 28 March 2025
First Online: 14 April 2025
Competing interests
: AL reports research funding from Gilead. KR: Kite/Gilead: Research Funding, Consultancy, Honoraria and travel support; Novartis: Honoraria; BMS/Celgene: Consultancy, Honoraria; Pierre-Fabre: travel support. MAP reports honoraria from Adicet, Allogene, Caribou Biosciences, Celgene, Bristol-Myers Squibb, Equilium, Exevir, ImmPACT Bio, Incyte, Karyopharm, Kite/Gilead, Merck, Miltenyi Biotec, MorphoSys, Nektar Therapeutics, Novartis, Omeros, OrcaBio, Sanofi, Syncopation, Takeda, VectivBio AG, and Vor Biopharma. He serves on DSMBs for Cidara Therapeutics and Sellas Life Sciences, and the scientific advisory board of NexImmune. He has ownership interests in NexImmune, Omeros and OrcaBio. He has received institutional research support for clinical trials from Allogene, Incyte, Kite/Gilead, Miltenyi Biotec, Nektar Therapeutics, and Novartis. RS: Received speaker honorarium from Incyte and Sanofi. GS Consultancy: AbbVie, BeiGene, BMS, Debiopharm, Epizyme, Genentech/Roche, Genmab, Innate Pharma, Incyte, Ipsen, Janssen, Kite/Gilead, Merck, Modex, Molecular Partners, Nurix, Orna Therapeutics, Pfizer, Treeline. Research funding: AbbVie, Genentech, Genmab, Janssen, Ipsen, and Nurix. MS served as a paid consultant for McKinsey & Company, Angiocrine Bioscience, Inc., and Omeros Corporation; received research funding from Angiocrine Bioscience, Inc., Omeros Corporation, Amgen Inc., Bristol Myers Squibb, and Sanofi; served on ad hoc advisory boards for Kite – A Gilead Company, and Miltenyi Biotec; and received honoraria from i3Health, Medscape, CancerNetwork, and IDEOlogy. The rest of co-authors declare no COIs.
